(19)
(11) EP 2 248 899 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.07.2015 Bulletin 2015/29

(45) Mention of the grant of the patent:
06.05.2015 Bulletin 2015/19

(21) Application number: 10171533.2

(22) Date of filing: 17.03.2004
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
C07K 16/28(2006.01)
C07K 14/705(2006.01)
G01N 33/68(2006.01)
 C07K 16/18(2006.01)
C07K 14/47(2006.01)
G01N 33/50(2006.01)

(54)

NOGO receptor binding protein

NOGO Rezeptor bindendes Protein

Protéine de liaison du récepteur NOGO

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 19.03.2003 US 455756 P
20.06.2003 US 480241 P
01.08.2003 US 492057 P

(43) Date of publication of application:
10.11.2010 Bulletin 2010/45

(60) Divisional application:
15160028.5

(62) Application number of the earlier application in accordance with Art. 76 EPC:
04757823.2 / 1606409

(73) Proprietor: Biogen MA Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • Mi, Sha
    Belmont, MA 02478 (US)
  • McCoy, John
    Reading, MA 01867 (US)
  • Pepinsky, R., Blake
    Arlington, MA 02474 (US)
  • Lee Daniel, H. S.
    Tung Chung Lantau (HK)
  • Lugovskoy, Alexey, A.
    Woburn, MA 01801 (US)

(74) Representative: Adams, Harvey Vaughan John 
Mathys & Squire LLP
The Shard 32 London Bridge Street London SE1 9SG
The Shard 32 London Bridge Street London SE1 9SG (GB)


(56) References cited: : 
WO-A-01/12662
 WO-A2-2007/008547
   
  • LI W ET AL: "NEUTRALIZATION OF MYELIN - ASSOCIATED NOGO - A BY A NOGO RECEPTOR - Fc FUSION PROTEIN" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, 2002, page ABS3332, XP001199824 ISSN: 0190-5295
  • MI SHA ET AL: "LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex." March 2004 (2004-03), NATURE NEUROSCIENCE, VOL. 7, NR. 3, PAGE(S) 221-228 , XP001183275 ISSN: 1097-6256 * figures 1,5,6 *
  • MI S ET AL: "A novel CNS - specific protein promotes axonal elongation by modulating RhoA signaling." 2003, SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, VOL. 2003, PAGE(S) ABSTRACT NO. 891.5 URL - HTTP://SFN.SCHOLARONE.COM , 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003 , XP001183276 * sentences 1-13 *
  • COLEMAN M P ET AL: "Axon pathology in neurological disease: a neglected therapeutic target", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 10, 1 October 2002 (2002-10-01), pages 532-537, XP004379947, ISSN: 0166-2236, DOI: 10.1016/S0166-2236(02)02255-5
  • HOWLAND DAVID S ET AL: "Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 3, 5 February 2002 (2002-02-05), pages 1604-1609, ISSN: 0027-8424
  • LI HE ET AL: "Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice", JOURNAL OF NEUROSCIENCE, vol. 21, no. 21, 1 November 2001 (2001-11-01), pages 8473-8481, ISSN: 0270-6474
  • MERRICK SANDRA E ET AL: "Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons (NT2N cells)", JOURNAL OF NEUROSCIENCE, vol. 17, no. 15, 1997, pages 5726-5737, ISSN: 0270-6474
  • GALVIN JAMES E ET AL: "Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 96, no. 23, 9 November 1999 (1999-11-09), pages 13450-13455, ISSN: 0027-8424
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1983, ARCHER A G ET AL: "THE NATURAL HISTORY OF ACUTE PAINFUL NEUROPATHY IN DIABETES MELLITUS", Database accession no. PREV198477029169
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).